KiroVAX 001

Drug Profile

KiroVAX 001

Alternative Names: KiroVAX001; TAPA-loaded DC vaccine - KiroVAX-001; TAPA-pulsed DC vaccine - KiroVAX-001; TAPA-pulsed dendritic cell vaccine - KiroVAX-001

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haematological malignancies

Most Recent Events

  • 28 Jul 2017 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater, Combination therapy) in USA (SC) (NCT02709993)
  • 10 Mar 2016 Kiromic plans a phase I/II trial for Haematological malignancies (Second-line therapy or greater, Combination therapy) in USA (SC) (NCT02709993)
  • 12 Feb 2015 Phase-I clinical trials in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top